Skip to main
ATRC
ATRC logo

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure Inc reported a substantial revenue growth of 16.6% year-over-year in Q4 2024, reaching $124.3 million, which exceeded analysts' expectations. The company's investment in research and development increased significantly to 28.1% of sales, reflecting commitment to innovation, including a notable $12 million upfront payment for co-development of PFA products. Additionally, the EBITDA margin improved to 10.2%, indicating stronger operational efficiency and potential for enhanced profit generation, supporting a positive long-term financial outlook for the company.

Bears say

AtriCure Inc faces several risks that contribute to a negative outlook, including disappointing sales from its EPi-Sense/Convergent products, lower than anticipated sales in Open Ablation and AtriClip segments, and potential market share loss to Medtronic's offerings. Revenue growth has slowed, projected to decrease to less than 11%, driven by underperformance in Minimally Invasive Ablation, Appendage Management, and Pain Management sectors. Additionally, both gross and operating margins have declined year-over-year, with gross margins at 74.5%, falling short of consensus expectations, indicating ongoing challenges in profitability and operational efficiency.

AtriCure (ATRC) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 14 analysts, AtriCure (ATRC) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.